Credit where credit is due, sounds like you had a fair audience with CEO. This is consistent with his behaviour that I have seen at AGM's and engaging with shareholders, he is part of the solution not the problem when I compare him to the narcissistic chairman.
There seems to be a common theme of "nothing is seamless" with all the explanations that you were given, put COVID aside as issues were abound pre 2020. Is it just the industry ? Is it the drugs we are choosing to clone ?
Totally agree with your view on Cashflow positive, they will announce in June/July that a, b and c has happened, we are withdrawing our guidance re cashflow giving at least 6 months head-way as the "earliest known time". That said it is probably a moot point as I believe no-one things it will eventuate and SP has factored to this view.
ACR Price at posting:
9.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
